

# Anita Deswal

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5338012/anita-deswal-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150  
papers

9,546  
citations

48  
h-index

96  
g-index

183  
ext. papers

11,685  
ext. citations

6.2  
avg, IF

5.81  
L-index

#	Paper	IF	Citations
150	Diuretic strategies in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 797-805	59.2	1012
149	Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). <i>Circulation</i> , <b>2001</b> , 103, 2055-9	16.7	781
148	Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1268-77	27.4	762
147	Ultrafiltration in decompensated heart failure with cardiorenal syndrome. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2296-304	59.2	577
146	Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 998-1005	15.1	455
145	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 2533-41	27.4	322
144	Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. <i>Circulation</i> , <b>1999</b> , 99, 3224-6	16.7	317
143	Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2016</b> , 134, e579-e646	16.7	314
142	Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 152-9	7.6	210
141	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. <i>Circulation</i> , <b>2015</b> , 131, 1763-71	16.7	173
140	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , <b>2019</b> , 140, e294-e324	16.7	168
139	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2016</b> , 134, e535-e578	16.7	164
138	Biomarkers of inflammation in heart failure. <i>Heart Failure Reviews</i> , <b>2010</b> , 15, 331-41	5	153
137	Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 422-8	15.1	144
136	Transitions of care in heart failure: a scientific statement from the American Heart Association. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 384-409	7.6	143
135	Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). <i>Journal of Cardiac Failure</i> , <b>2011</b> , 17, 634-42	3.3	138
134	Metformin use and mortality in ambulatory patients with diabetes and heart failure. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 53-8	7.6	137

133	Quantification of the myocardial response to low-dose dobutamine using tissue Doppler echocardiographic measures of velocity and velocity gradient. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 615-23	3	133
132	Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 415-26	15.1	125
131	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e013757	6	102
130	Impact of race on health care utilization and outcomes in veterans with congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 778-84	15.1	99
129	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 653-9	7.6	98
128	Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 123-30	7.6	97
127	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2019</b> , 95, 1304-1317	9.9	96
126	Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 21-6	3	96
125	Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, 390-8	3.3	86
124	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, e159-e240	15.1	82
123	Cardiac involvement in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , <b>1996</b> , 22, 841-60	2.4	76
122	Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 176-82 <sup>3</sup>	3	72
121	Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. <i>Chest</i> , <b>2003</b> , 123, 716-24	5.3	72
120	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , <b>2016</b> , 133, 631-8	16.7	69
119	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk—the atherosclerosis risk in communities study. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 1802-10	5.5	69
118	Obesity as a prognostic factor in chronic symptomatic heart failure. <i>American Heart Journal</i> , <b>2005</b> , 150, 1233-9	4.9	69
117	Comparison of morbidity in women versus men with heart failure and preserved ejection fraction. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 1228-31	3	68
116	An overview of tumor necrosis factor alpha and the failing human heart. <i>Current Opinion in Cardiology</i> , <b>1999</b> , 14, 206-10	2.1	68

115	Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2743-9	15.1	65
114	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , <b>2015</b> , 36, 939-45	9.5	62
113	A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. <i>International Journal of General Medicine</i> , <b>2010</b> , 3, 279-86	2.3	62
112	The role of cytokines in disease progression in heart failure. <i>Current Opinion in Cardiology</i> , <b>1997</b> , 12, 218-23		61
111	Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 380-400	3.3	58
110	Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 373-7	3	58
109	Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006513	7.6	56
108	Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. <i>American Heart Journal</i> , <b>2006</b> , 152, 348-54	4.9	56
107	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 1052-8	7.6	54
106	New therapeutics for chronic heart failure. <i>Annual Review of Medicine</i> , <b>2002</b> , 53, 59-74	17.4	54
105	Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 111-21	15.1	50
104	Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 533-41	7.6	49
103	Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 412-21	7.9	48
102	Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1834-8	3	46
101	Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. <i>Journal of Cardiac Failure</i> , <b>2009</b> , 15, 293-9	3.3	44
100	Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. <i>American Heart Journal</i> , <b>2011</b> , 161, 567-73	4.9	43
99	Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1803-1812	15.1	40
98	The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes. <i>American Journal of Surgery</i> , <b>2008</b> , 196, 720-5	2.7	40

97	Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1963-5	59.2	38
96	Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 3741-6	3.2	35
95	Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 560-8	3.3	33
94	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1144-1149	3	33
93	Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction. <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 1003-7	3	31
92	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 2527-2536	15.1	29
91	The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 32-6	15.1	29
90	Echocardiographic changes during treatment of acute decompensated heart failure: insights from the ESCAPE trial. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 792-8	3.3	28
89	Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , <b>2019</b> , 139, e879-e886	16.7	26
88	The potentially modifiable burden of incident heart failure due to obesity: the atherosclerosis risk in communities study. <i>American Journal of Epidemiology</i> , <b>2010</b> , 172, 781-9	3.8	26
87	New predictive models of heart failure mortality using time-series measurements and ensemble models. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 456-62	7.6	26
86	Trials within trials: confirmatory subgroup analyses in controlled clinical experiments. <i>Contemporary Clinical Trials</i> , <b>2001</b> , 22, 605-19		26
85	Diastolic dysfunction and diastolic heart failure: mechanisms and epidemiology. <i>Current Cardiology Reports</i> , <b>2005</b> , 7, 178-83	4.2	25
84	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. <i>International Journal of Cardiology</i> , <b>2017</b> , 233, 61-66	3.2	24
83	Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. <i>American Heart Journal</i> , <b>2007</b> , 153, 515-22	4.9	24
82	Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. <i>Population Health Management</i> , <b>2018</b> , 21, 209-216	1.8	23
81	Predicting quality of life in veterans with heart failure: the role of disease severity, depression, and comorbid anxiety. <i>Behavioral Medicine</i> , <b>2010</b> , 36, 70-6	4.4	22
80	Worsening renal function is not associated with response to treatment in acute heart failure. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 1912-7	3.2	19

79	New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 183-93	3.3	19
78	Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. <i>Cardiology Clinics</i> , <b>2008</b> , 26, 1-14, v	2.5	19
77	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 866-874	9.5	19
76	Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 56-63	7.9	18
75	Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 145-9	3.3	18
74	Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1682-1690	8.9	17
73	Recurrent low-level troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. <i>International Journal of Cardiology</i> , <b>2013</b> , 166, 394-8	3.2	17
72	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure - A Pilot Study. <i>Journal of Obesity &amp; Weight Loss Therapy</i> , <b>2012</b> , 2, 1-8	0	17
71	Decreasing body temperature predicts early rehospitalization in congestive heart failure. <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 489-96	3.3	16
70	Variation by race in factors contributing to heart failure hospitalizations. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 23-9	3.3	16
69	Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. <i>Chest</i> , <b>2001</b> , 120, 453-9	5.3	16
68	Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. <i>International Journal of Cardiology</i> , <b>2014</b> , 172, 239-41	3.2	15
67	Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data. <i>International Journal of Cardiology</i> , <b>2011</b> , 150, 264-9	3.2	15
66	Mortality after hospitalization for heart failure in blacks compared to whites. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 694-700	3	15
65	Spironolactone in pulmonary arterial hypertension: results of a cross-over study. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894019898030	2.7	14
64	Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 2030-2034	3	13
63	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 233-40	2.6	13
62	Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 270-5	3	13

61	Depression and anxiety in ambulatory patients with heart failure. <i>Psychosomatics</i> , <b>2009</b> , 50, 592-8	2.6	13
60	The metabolic syndrome and mortality in an ethnically diverse heart failure population. <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 590-5	3.3	12
59	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1329-1337	16.2	12
58	COVID-19 myocarditis and long-term heart failure sequelae. <i>Current Opinion in Cardiology</i> , <b>2021</b> , 36, 234-240	2.4	11
57	Relation between playing position and coronary artery calcium scores in retired National Football League players. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1836-40	3	10
56	Complex antithrombotic therapy: determinants of patient preference and impact on medication adherence. <i>Patient Preference and Adherence</i> , <b>2015</b> , 9, 1657-68	2.4	9
55	Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1725-1735	12.3	9
54	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2021</b> , 162, e23-e106	1.5	9
53	Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. <i>International Journal of Obesity</i> , <b>2020</b> , 44, 1561-1567	5.5	8
52	Anti-angiotensin therapy: new perspectives. <i>Cardiology Clinics</i> , <b>2007</b> , 25, 573-80; vi-vii	2.5	8
51	Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , <b>2021</b> , 144, 1521-1523	16.7	8
50	Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. <i>International Journal of Cardiology</i> , <b>2020</b> , 313, 1-8	3.2	7
49	Prevention of "Failure": Is It a Failure of Prevention?. <i>Circulation</i> , <b>2018</b> , 137, 106-108	16.7	7
48	Acute Kidney Injury With Ventricular Assist Device Placement: National Estimates of Trends and Outcomes. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 650-658	7.4	6
47	Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. <i>Cardiovascular Therapeutics</i> , <b>2013</b> , 31, 291-7	3.3	6
46	The fragility of cardiovascular clinical trial results. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, 247-53	3.3	6
45	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 449-55	4.4	6
44	Cardiovascular Toxicities of Androgen Deprivation Therapy. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 47	5.4	6

43	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 513-522	9.7	6
42	Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , <b>2018</b> , 14, 525-535	3.3	6
41	Advances in the treatment of heart failure with a preserved ejection fraction. <i>Current Opinion in Cardiology</i> , <b>2008</b> , 23, 233-40	2.1	5
40	Aldosterone Receptor Blockers in the Treatment of Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2004</b> , 6, 327-334	2.1	5
39	Modern Radiotherapy and Risk of Cardiotoxicity. <i>Chemotherapy</i> , <b>2020</b> , 65, 65-76	3.2	5
38	COVID-19 and Cardiovascular Health Among Patients with Cancer. <i>Current Cardiology Reports</i> , <b>2020</b> , 22, 171	4.2	5
37	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 559-571	15.1	5
36	Treatment of patients with heart failure and preserved ejection fraction. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2008</b> , 10, 516-28	2.1	4
35	Long-term results of coronary artery bypass grafting in patients with ischemic cardiomyopathy: the impact of renal insufficiency and noncardiac vascular disease. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 206-12 <sup>3</sup>	2.3	4
34	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. <i>Journal of Immunotherapy and Precision Oncology</i> , <b>2020</b> , 3, 113-120 <sup>6</sup>	2.6	4
33	Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014669	6	4
32	Coronary artery disease performance measures and statin use in patients with recent percutaneous coronary intervention or recent coronary artery bypass grafting (from the NCDR PINNACLE registry). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1013-8	3	3
31	Case report: isolated cardiac amyloidosis: an enigma unravelled. <i>Methodist DeBakey Cardiovascular Journal</i> , <b>2015</b> , 11, 53-8	2.1	3
30	De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 72, 223-233	7.4	3
29	Trends in Left Ventricular Assist Device Implantation and Associated Mortality Among Patients With and Without ESRD. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 72, 620-622	7.4	3
28	Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. <i>Redox Biology</i> , <b>2021</b> , 47, 102132	11.3	3
27	Response to Letter Regarding Article, Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 840	7.6	2
26	Readmissions after Acute Kidney Injury during Left Ventricular Assist Device Implantation Hospitalization. <i>American Journal of Nephrology</i> , <b>2020</b> , 51, 172-181	4.6	2



25	Senescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 763930	5.4	2
24	Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines-Heart Failure Registry. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e018696	6	2
23	Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience.. <i>Open Heart</i> , <b>2021</b> , 8,	3	2
22	Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy. <i>JACC: Case Reports</i> , <b>2020</b> , 2, 2095-2100	1.2	1
21	Ularitide in Acute Heart Failure. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2018</b> , 6, 17-23	0.9	1
20	An overview of a different type of cardio-oncology gathering: summary of the COMP (cardio-oncology multidisciplinary practice) meeting held in Houston Texas, January 2020. <i>Cardio-Oncology</i> , <b>2020</b> , 6, 20	2.8	1
19	Cardio-Oncology: Learning From the Old, Applying to the New. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 601893	5.4	1
18	Iron deficiency and iron therapy in heart failure and chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2020</b> , 29, 508-514	3.5	1
17	Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e004817	5.8	1
16	Obesity and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , <b>2021</b> , 17, 345-356	3.3	1
15	Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment.. <i>Current Oncology Reports</i> , <b>2022</b> , 24, 543	6.3	1
14	Understanding by General Providers of the Echocardiogram Report. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 296-302	3	0
13	Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 734820	5.4	0
12	Rate of Progression of Aortic Stenosis in Patients With Cancer. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 644264	5.4	0
11	Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?. <i>Current Atherosclerosis Reports</i> , <b>2021</b> , 23, 61	6	0
10	In AF and HF, catheter ablation vs medical therapy reduced mortality and hospitalization for worsening HF. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, JC55	8	
9	NT-proBNP-guided and conventional therapies did not differ for readmission or mortality in acute decompensated HF. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, JC21	8	
8	Role and optimal dosing of angiotensin-converting enzyme inhibitor therapy. <i>Heart Failure Clinics</i> , <b>2005</b> , 1, 25-37	3.3	

- 7 Perils of the random experiment. *American Journal of Therapeutics*, **2003**, 10, 112-21 1
- 6 Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 502-3
- 5 In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization. *Annals of Internal Medicine*, **2020**, 173, JC51 8
- 4 Geographical Differences in Cardiovascular Comorbidities and Outcomes of COVID-19 Hospitalized Patients in the USA. *Cardiology*, **2021**, 146, 481-488 1.6
- 3 In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo. *Annals of Internal Medicine*, **2021**, 174, JC69 8
- 2 Asymptomatic left ventricular dysfunction: an overlooked part of the continuum of heart failure. *Heart Failure Monitor*, **2002**, 3, 42-8
- 1 Review: B-type natriuretic peptide consistently predicts death and cardiovascular events in heart failure. *ACP Journal Club*, **2005**, 143, 53